Products
Naptumomab Biosimilar Fab Fusion Protein (5T4) for Research
Pre-Made Naptumomab biosimilar, Fab Fusion, Anti-TPBG Antibody: Anti-5T4/M6P1/5T4AG/WAIF1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-363-1mg | 1mg | |
| GMP-Bios-ab-363-10mg | 10mg | |
| GMP-Bios-ab-363-100mg | 100mg | |
| GMP-Bios-ab-363-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Naptumomab biosimilar, Fab Fusion, Anti-TPBG Antibody: Anti-5T4/M6P1/5T4AG/WAIF1 therapeutic antibody |
| INN Name | Naptumomab |
| Target | TPBG |
| Format | Fab Fusion |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2006 |
| Year Recommended | 2007 |
| Companies | Active Biotech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Non-small cell lung cancer;Pancreatic cancer;Renal cancer |
| Development Tech | na |
About target - TPBG
1. Protein Trophoblast glycoprotein
2. Gene TPBG
3. Organism Homo sapiens (Human)
Function
May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization.
Miscellaneous
Antigen 5T4 is overexpressed by a wide spectrum of cancers, including colorectal, ovarian and gastric, but with a limited normal tissue expression. Could be used for tumor immunotherapy.
Reduction of TPBG levels by siRNA significantly enhanced the beta-catenin/TCF transcription-based reporter pBAR activation in response to Wnt stimulation.
